1. nAMD: Switching Therapies - what you need to know

3. Program Goal

4. Currently Available Anti-VEGF Therapies Used to Treat nAMD

5. 12-Month Outcomes of Ranibizumab vs Aflibercept: Similar Rates of VA Improvement

6. Factors That Determine The Reason to Switch Therapies

7. EMR Study: Real World Ranibizumab Data Vs Benchmark Standards of Care

8. Real-World Visual Outcomes at Centers Across UK Differ From Randomized Trials

9. Is It Beneficial for a Patient to Switch?

10. Results May Vary After Switching Therapies

11. Two Main Reasons for Switching Therapies

12. Visual Function of Patient is Most Important

13. Can Anatomical Endpoints Guide Decisions to Switch Therapies?

14. Benefit of Switching: Theory

15. Switching From Ranibizumab to Aflibercept: Real-Life Data

16. Switching From Ranibizumab to Aflibercept: Real-Life Data (cont)

17. Significance of Switching: Study Results

18. The Mechanisms of Tachyphylaxis

19. Meta-Analysis of Studies of Patients With Treatment Resistant nAMD: Methods

20. Meta-Analysis Indicates High Number of Injections May Cause Resistance

21. Concepts of Tachyphylaxis: More Data is Needed

22. Concepts of Tachyphylaxis: Change in Underlying Disease

23. Factors That Involve Decisions to Switch Therapies

24. CATT Study: Results Show Discontinuous Therapy Inferior to Continuous Therapy

25. Real-Life Data Studies May Differ From Clinical Trial Data

26. Response to Anti-VEGF Therapy in nAMD

27. Is a Loading Phase Needed After Switching?

28. Patient Case Scenario

29. Switching Study: Ranibizumab to Aflibercept to Ranibizumab

30. Concluding Remarks

31. Abbreviations

32. Abbreviations (cont)